Filing Details
- Accession Number:
- 0001209191-20-059196
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-11-18 18:09:51
- Reporting Period:
- 2020-11-16
- Accepted Time:
- 2020-11-18 18:09:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1000694 | Novavax Inc | NVAX | Biological Products, (No Disgnostic Substances) (2836) | 222816046 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1342826 | C Stanley Erck | C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-11-16 | 42,499 | $39.80 | 62,993 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-11-16 | 9,818 | $25.60 | 72,811 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-11-16 | 5,766 | $87.20 | 67,045 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-16 | 8,306 | $88.36 | 58,739 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-16 | 11,234 | $89.26 | 47,505 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-16 | 4,598 | $90.61 | 42,907 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-16 | 17,503 | $92.97 | 25,404 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-11-16 | 4,909 | $93.56 | 20,495 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to buy) | Disposition | 2020-11-16 | 42,499 | $0.00 | 42,499 | $39.80 |
| Common Stock | Stock Option (Right to buy) | Disposition | 2020-11-16 | 9,818 | $0.00 | 9,818 | $25.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-06-22 | No | 4 | M | Direct | |
| 35,182 | 2022-03-01 | No | 4 | M | Direct |
Footnotes
- The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.95 to $87.92, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.95 to $88.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.97 to $89.96, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.99 to $90.90, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.21 to $93.205, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.21 to $93.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote
- The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the June 22, 2011 grant date.
- The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date.
Billionaire Hedge Funds
